1. |
JemalA, SiegelR, Xu J, et al. Cancer statisties[J]. CA Cancer J Clin, 2010, 60(13):277-300.
|
2. |
崔恒. 卵巢癌的早期诊断[J]. 中国妇产科临床杂志, 2010, 11(6):403-405.
|
3. |
Bafna S, Kaur S, Batra SK. Membrane-bound mucins:the mechanistic basis for alterations in the growth and survival of cancer cells[J]. Oncogene, 2010, 29(20):2893-2904.
|
4. |
Reis CA, Osorio H, Silva L, et al. Alterations in glycosylation as biomarkers for cancer detection[J]. J Clin Pathol, 2010, 63(4):322-329.
|
5. |
Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer[J]. Curr Opin Oncol, 2010, 22(5):492-497.
|
6. |
Romero I, Bast RC. Minireview:human ovarian cancer:biology, current management, and paths to personalizing therapy[J]. Endocrinology, 2012, 153(4):1593-1602.
|
7. |
Werdelin O, Meldal M, Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells[J]. Proc Natl Acad Sci USA, 2002, 99(15):9611-9613.
|
8. |
Kim D, Jung WH, Koo JS. Expression of MUC1, MUC2, MUC5AC and MUC5B in mucinous lesions of the breast[J]. Pathobiology, 2012, 79(3):144-153.
|
9. |
Quin RJ, Mcguckin MA. Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion[J]. Int J Cancer, 2000, 87(4):499-506.
|
10. |
Dong Y, Walsh MD, Cummings MC, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours[J]. J Pathol, 1997, 183(3):311-317.
|
11. |
刘颖, 史惠蓉, 魏丽惠, 等. 肿瘤相关粘蛋白MUC1及其同种型MUC1/Y与卵巢上皮性肿瘤关系的研究[J]. 中国实用妇科与产科杂志, 2003, 19(5):26-28.
|
12. |
安锦丹, 王静芬, 程慧, 等. 黏蛋白MUC1、MUC2和MUC5AC在卵巢上皮性肿瘤中的表达及意义[J]. 中华病理学杂志, 2004, 33(5):468-469.
|
13. |
Feng H, Ghazizadeh M, Konishi H, et al. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas[J]. Jpn J Clin Oncol, 2002, 32(12):525-529.
|
14. |
Wang L, Ma J, Liu F, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance[J]. Gynecol Oncol, 2007, 105(3):695-702.
|
15. |
Catharina HE, Frings PH. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer[J]. Histopathology, 2010, 57(4):597-606.
|
16. |
Chauhan SC, Singh AP, Ruiz F, et al. Aberrant expression of MUC4 in ovarian carcinoma:diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)[J]. Mod Pathol, 2006, 19(10):1386-1394.
|
17. |
Van Elssen CH, Frings PW, Bot FJ, et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer[J]. Histopathology, 2010, 57(4):597-606.
|
18. |
Singh AP, Senapati S, Ponnusamy MP, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer[J]. Lancet Oncol, 2008, 9(11):1076-1085.
|
19. |
Deng J, Wang L, Chen H, et al. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression[J]. Cancer Metastasis Rev, 2013, 32(3/4):535-551.
|
20. |
Jeschke U, Wiest I, Schumacher AL, et al. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab[J]. Anticancer Res, 2012, 32(5):2185-2189.
|
21. |
Shahbazi-Gahrouei D, Abdolahi M. Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging[J]. Sci World J, 2013(2013):609151.
|
22. |
Engelstaedter V, Heublein S, Schumacher AL, et al. Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients[J]. BMC Cancer, 2012, 12(15):600.
|
23. |
Zhang D, Gao J, Zhu L, et al. Chemoresistance is associated with MUC1 and Lewisy antigen expression in ovarian epithelial cancers[J]. Int J Mol Sci, 2013, 14(6):11024-11033.
|
24. |
Ricardo S, Marcos-Silva L, Pereira D, et al. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours[J]. Mol Oncol, 2015, 9(2):503-512.
|
25. |
Janssen ML, Pels W, Massuger LF, et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model:Effect of the radionuclide[J]. Int J Gynecol Cancer, 2003, 13(5):607-613.
|
26. |
Dai F, Zhang Y, Zhu X, et al. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation[J]. Target Oncol, 2012, 7(4):217-225.
|
27. |
Dai F, Zhang Y, Zhu X, et al. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer[J]. Gynecol Oncol, 2013, 131(2):451-459.
|
28. |
Liu N, Zhou C, Zhao J, et al. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera[J]. Cancer Invest, 2012, 30(8):577-582.
|
29. |
Mony JT, Zhang L, Ma T, et al. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model[J]. Cancer Immunol Immunother, 2015, 64(9):1095-1108.
|
30. |
Wang L, Chen H, Liu F, et al. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer[J]. Cancer Lett, 2011, 300(2):122-133.
|
31. |
Wang L, Chen H, Pourgholami MH, et al. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model[J]. PLoS One, 2011, 6(9):e24405.
|
32. |
Welinder C, Baldetorp B, Borrebaeck C, et al. A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity[J]. Glycobiology, 2011, 21(8):1097-1107.
|